Sequenom Names Steven Owings Vice President of Commercial Development, Prenatal Diagnostics

Except for the historical information contained in this press release, the matters set forth herein, including statements regarding Sequenom's commercialization of its non-invasive prenatal diagnostic technology, expected application of Sequenom's non-invasive technology for fetal Rhesus D...

Full description

Saved in:
Bibliographic Details
Published inPR Newswire
Format Newsletter
LanguageEnglish
Published New York PR Newswire Association LLC 05.02.2007
Subjects
Acquired immune deficiency syndrome
AIDS
Appointments & personnel changes
Commercialization
Diagnostics
Executives
FDA approval
Genetic testing
HIV
Human immunodeficiency virus
Industrial development
Laboratories
Marketing
Owings, Steven
Product development
United States > US
Online AccessGet full text

Cover

More Information
Summary:Except for the historical information contained in this press release, the matters set forth herein, including statements regarding Sequenom's commercialization of its non-invasive prenatal diagnostic technology, expected application of Sequenom's non-invasive technology for fetal Rhesus D typing and its availability during the first half of this year, the future contributions of Mr. [Steven Owings] to Sequenom and the opportunity for Mr. Owings, Sequenom's work to build a non-invasive prenatal diagnostic franchise, create value, and maximize commercial opportunities, the potential of Sequenom's non-invasive approach to prenatal genetic testing to create a paradigm shift away from highly invasive procedures, and Sequenom's plans to develop and commercialize non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with reliance upon the efforts of other parties, new technology development, product development and commercialization, competition, government regulation, obtaining or maintaining regulatory approvals, market acceptance of technology and products including Sequenom's non-invasive prenatal diagnostic technology, and other risks detailed from time to time in Sequenom's SEC filings, including Sequenom's Annual Report on Form 10-K for the year ended December 31, 2005, Sequenom's most recently filed quarterly report on Form 10-Q, and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission (SEC). These forward-looking statements are based on current information that is likely to change. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.